DOCSLIB.ORG

Understanding Hemochromatosis Hemochromatosis Is a Disorder in Which the Body Absorbs Too Much Iron

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Understanding Hemochromatosis Hemochromatosis Is a Disorder in Which the Body Absorbs Too Much Iron Understanding Hemochromatosis Hemochromatosis is a disorder in which the body absorbs too much iron. Usually inherited, it can also be caused by repeated blood transfusions, sickle cell anemia, liver disease or alcoholism. Healthy people absorb about 8 to 10 percent of the iron they consume through diet. If you have hemochromatosis, you can absorb four times more iron than normal; over time, you may retain 5 to 20 times the amount of iron the body needs. Untreated, excess iron can accumulate in the liver, heart, pancreas, thyroid and other organs, leading to liver disease, diabetes, heart attack, hypothyroidism and other serious or life-threatening medical conditions. Symptoms If you inherit two copies of the same mutations can be tested for, nor does The most common complaint is joint mutations, you are a homozygote. If you their presence mean that you will pain. Other symptoms include: inherit two different mutations, you are a experience hemochromatosis. compound heterozygote. The exact muta- • fatigue/lack of energy Treatment • abdominal pain tions determine your likelihood of risk • unexplained weight loss or weight gain for iron overload. Only 1 in 400 people is Treatment aims to remove excess iron • loss of sex drive likely to have genetic mutations in both from the blood and treat organ damage. copies of the HFE gene. • irritability Periodic phlebotomy (therapeutic • bronze or yellowish skin color Diagnosis blood removal) is similar to regular Sometimes there are no symptoms; a Hemochromatosis is usually discovered blood donation but requires a doctor’s routine physical exam or blood test through a routine blood test. Specific order. You may initially need to donate reveals the condition. Because many tests may cover these areas: as often as once or twice a week, then medical conditions can cause similar less often (but still regularly) as iron Transferrin saturation (TS): symptoms, it is important to see your • The levels drop to normal. It is safe to donate doctor for further evaluation. best measure of excess iron storage, to blood banks and hospitals. this blood test measures how much Genetics iron is bound to the protein that If you have hereditary hemochromatosis, Hereditary hemochromatosis is most carries iron in the blood. but have not experienced organ damage, Ferritin: often caused by abnormalities in the • Levels of this protein in phlebotomy can improve issues, like gene HFE, which helps control the the blood indicate how much iron is fatigue and abdominal pain—but other amount of iron absorbed from food. stored in the liver and the chance of issues (joint paint and diabetes) will Everyone inherits two copies of HFE, liver damage. likely be unaffected by treatment. Liver biopsy: one from each parent. Two specific • This allows a physician Recommended dietary changes mutations of this gene account for the to see how much iron is accumulating include consuming less iron and vast majority of iron overload: C282Y and whether there is inflammation or avoiding iron and vitamin C and H63D. (There are also other, less cirrhosis (scarring). Genetic testing: supplements (vitamin C enhances iron common genetic causes.) • This is best used after diagnosis to understand why absorption). If you have liver damage, If you inherit one mutated (altered) copy, someone has hemochromatosis and your doctor may advise you to avoid you are a carrier, or heterozygote. You to determine which, if any, genetic alcohol and raw seafood. will not have hemochromatosis, but you mutations caused it. It is good could pass it on to your children. to remember that not all genetic Disclaimer/Disclosure: © 2012 Johns Hopkins University. All rights reserved. All information is intended for your general knowledge only and is not a substitute for medical advice or treatment for specific medical conditions. You should seek prompt medical care for any specific health issues and consult your physician before starting a new fitness regimen..
Load more

Recommended publications
  • Evaluation of Iron Profile in Type II Diabetes Mellitus Cases
    International Journal of Biotechnology and Biochemistry ISSN 0973-2691 Volume 15, Number 1 (2019) pp. 27-37 © Research India Publications http://www.ripublication.com Evaluation of Iron Profile in Type II Diabetes Mellitus Cases Dr. Sayantaann Saha*, Dr. Roopa Murgod Department of Biochemistry Vydehi Institute of Medical Sciences and Research Centre, EPIP Area, Whitefield, Bangalore 560066, India. ABSTRACT Introduction: Type 2 diabetes mellitus is the most common metabolic disorder, characterized by chronic hyperglycemia resulting from defects in insulin secretion, insulin action, or both. Iron, a transitional metal has been shown to play a major role in pathogenesis of T2DM with a bi-directional relationship where iron affects glucose metabolism, and glucose metabolism in turn impinges on several iron metabolic pathways. Aims or Objectives: To estimate and compare the parameters related to iron metabolism viz. Serum Iron (Fe), Serum Ferritin, Serum TIBC (Total Iron Binding Capacity), Serum Transferrin and Transferrin Saturation with Fasting Blood Sugar (FBS) between T2DM patients and healthy controls and correlation of FBS with the above iron parameters. Material and methods: A case control study was conducted between 41 cases of confirmed T2DM patients and 40 age & sex matched healthy controls. Iron profile parameters & FBS were estimated in both the groups and compared. Iron parameters were also correlated with FBS. * Corresponding author(Dr. Sayantaann Saha), Email id: [email protected] 28 Dr. Sayantaann Saha, Dr. Roopa Murgod Results: Serum ferritin, Serum iron & serum transferrin saturation were found to be significantly higher in patients with T2DM compared to control group (P<0.001). Serum transferrin & serum TIBC were found to be slightly lower in cases as compared to controls (P<0.001).
    [Show full text]
  • HEMOCHROMATOSIS GENOTYPES and ELEVATED TRANSFERRIN SATURATION - Risk of Diabetes Mellitus, Hypertension,Cancer, and Total Mortality
    Doctor of Medical Science Thesis by Christina Ellervik MD, PhD HEMOCHROMATOSIS GENOTYPES AND ELEVATED TRANSFERRIN SATURATION - risk of diabetes mellitus, hypertension,cancer, and total mortality Aected Unaected Carrier Carrier Carrier Father Mother Aected Carrier Carrier Unaected Son Daughter Son Daughter Hemochromatosis genotypes and elevated transferrin saturation - risk of diabetes mellitus, hypertension,cancer, and total mortality Doctor of Medical Science Thesis by Christina Ellervik MD,PhD PhD The Faculty of Health and Medical Sciences at the University of Copenhagen has accepted this dissertation, which consists of the already published dissertations listed below, for pub- lic defence for the doctoral degree in medicine. Copenhagen, October 11th 2015 Ulla M. Wewer Head of Faculty Place and time for defence: St. Auditorium at Herlev Hospital, June 22nd 2016 at 2pm Table of Contents • Papers on which the thesis is based............................................................. 2 • Preface ............................................................................................................. 3 • Scope and delimitation of the thesis ...................................................... 3 - 4 • Introduction ............................................................................................ 4 - 14 Hereditary hemochromatosis ............................................................................................ 4 - 7 Diabetes mellitus (paper 1 and 2) .....................................................................................
    [Show full text]
  • The Acute Phase Response and Exercise: Court and Field Sports
    170 Br J Sports Med 2001;35:170–173 The acute phase response and exercise: court and Br J Sports Med: first published as 10.1136/bjsm.35.3.170 on 1 June 2001. Downloaded from field sports K E Fallon, S K Fallon, T Boston Abstract capacity, and transferrin, and transferrin satu- Objective—To determine the presence or ration.45 absence of an acute phase response after A number of studies have documented training for court and field sports. aspects of the acute phase response after exer- Participants—All members of the Aus- cise of a duration that would be expected to tralian women’s soccer team (n = 18) and induce significant damage to skeletal 6–12 all members of the Australian Institute of muscle. No data are available on the acute Sport netball team (n = 14). phase response in relation to court and field Methods—Twelve acute phase reactants sports. (white blood cell count, neutrophil count, Documentation of the extent and nature of platelet count, serum iron, ferritin, and the acute phase response to various types of transferrin, percentage transferrin satu- exercise is important, as changes related to the response may need to be taken into account for ration, á1 antitrypsin, caeruloplasmin, á2 acid glycoprotein, C reactive protein, and interpretation of haematological and biochemi- erythrocyte sedimentation rate) were cal measurements made during and after participation in sport. measured during a rest period and after The aim of this prospective study was there- moderate and heavy training weeks in fore to determine the presence or absence of members of elite netball and women’s the acute phase response in sports representa- soccer teams.
    [Show full text]
  • Elevated Serum Transferrin Saturation and Mortality
    Elevated Serum Transferrin Saturation and Mortality 1 Arch G. Mainous III, PhD ABSTRACT 1 James M. Gill, MD, MPH BACKGROUND A large proportion of US adults have elevated transferrin satura- Peter J. Carek, MD, MS2 tion, an indicator of a predisposition for iron overload. The purpose of this study was to evaluate the relationship between elevated serum transferrin saturation 1 Department of Family Medicine, Medical and mortality. University of South Carolina, Charleston, SC METHODS This cohort study was conducted using data from the First Health and 2Department of Family & Community Medicine, Christiana Care Health System, Nutrition Examination Survey I (1971–1974) (NHANES I) merged with the NHANES Wilmington, Del I Epidemiologic Followup Study (1992) (N = 10,714). We used SUDAAN and appro- priate weights to make population estimates for the adult US population (aged 25 to 74 years at baseline). All-cause mortality was evaluated in relation to serum transferrin saturation of greater than 45%, greater than 50%, greater than 55%, and greater than 60% using Cox proportional hazards regression. RESULTS In a Cox proportional hazards model controlling for potential confound- ers, including comorbid diseases, smoking, and cholesterol, all-cause mortality is signifi cantly greater for persons with a serum transferrin saturation of more than 55%, compared with those with saturations below this cutoff (hazards ratio [HR] =1.60, 95% confi dence interval [CI], 1.17-2.21). No one who died had hemochromatosis as any of the 20 listed causes of death. Many of the underlying causes of death for persons with serum transferrin saturation levels of more than 55% are common causes of death in the general population, although these per- sons were more likely to have died of cirrhosis and diabetes, a fi nding consistent with iron overload.
    [Show full text]
  • Nutrient Deficiency and Drug Induced Cardiac Injury and Dysfunction
    Editorial Preface to Hearts Special Issue “Nutrient Deficiency and Drug Induced Cardiac Injury and Dysfunction” I. Tong Mak * and Jay H. Kramer * Department of Biochemistry and Molecular Medicine, The George Washington University Medical Center, Washington DC, WA 20037, USA * Correspondence: [email protected] (I.T.M.); [email protected] (J.H.K.) Received: 30 October 2020; Accepted: 1 November 2020; Published: 3 November 2020 Keywords: cardiac injury/contractile dysfunction; micronutrient deficiency; macromineral deficiency or imbalance; impact by cardiovascular and/or anti-cancer drugs; systemic inflammation; oxidative/nitrosative stress; antioxidant defenses; supplement and/or pathway interventions Cardiac injury manifested as either systolic or diastolic dysfunction is considered an important preceding stage that leads to or is associated with eventual heart failure (HF). Due to shifts in global age distribution, as well as general population growth, HF is the most rapidly growing public health issue, with an estimated prevalence of approximately 38 million individuals globally, and it is associated with considerably high mortality, morbidity, and hospitalization rates [1]. According to the US Center for Disease Control and The American Heart Association, there were approximately 6.2 million adults suffering from heart failure in the United States from 2013 to 2016, and heart failure was listed on nearly 380,000 death certificates in 2018 [2]. Left ventricular systolic heart failure means that the heart is not contracting well during heartbeats, whereas left ventricular diastolic failure indicates the heart is not able to relax normally between beats. Both types of left-sided heart failure may lead to right-sided failure. There have been an increasing number of studies recognizing that the deficiency and/or imbalance of certain essential micronutrients, vitamins, and macrominerals may be involved in the pathogenesis of cardiomyopathy/cardiac injury/contractile dysfunction.
    [Show full text]
  • Differentiation of Iron Deficiency and the Anemia of Chronic Disease
    Differentiation of Iron Deficiency and the Anemia of Chronic Disease Danis J. Christensen, MD Salt Lake City, Utah The predictive value positive of serum iron studies and eryth­ rocyte indices in differentiating between iron deficiency ane­ mia and the anemia of chronic disease (ACD) were determined in 82 hospitalized patients with an iron-binding saturation of 15 percent or less. Iron deficiency, determined by serum ferritin of 20 ng/mL or less, was present in only 31 percent of patients with a serum iron level of 10 p-g/dL or less; 39 percent of patients with a transferrin saturation of 5 percent or less, and 54 percent of patients with a total iron-binding capacity (TIBC) of 350 /zg/dL or greater; conversely, iron deficiency was pres­ ent in only 3 percent of patients with a TIBC of 250 p,g/dL or less. Iron deficiency was present in 83 percent of patients with a mean corpuscular volume (MCV) of 75 /xm3 or less, but only 2 percent of patients with an MCV of 86 p,m3 or greater. It is concluded that the MCV has strong predictive value positive (and negative) when below (or above) the values just cited, but that serum iron studies do not have sufficient predictive value to justify their use in the routine differentiation between iron deficiency anemia and the ACD in hospitalized patients when no other cause for anemia is likely. One of the most frequent problems in the diag­ parameters commonly used to differentiate be­ nosis of anemia is the differentiation between tween the two conditions.
    [Show full text]
  • Diagnosis and Treatment of Wilson Disease: an Update
    AASLD PRACTICE GUIDELINES Diagnosis and Treatment of Wilson Disease: An Update Eve A. Roberts1 and Michael L. Schilsky2 This guideline has been approved by the American Asso- efit versus risk) and level (assessing strength or certainty) ciation for the Study of Liver Diseases (AASLD) and rep- of evidence to be assigned and reported with each recom- resents the position of the association. mendation (Table 1, adapted from the American College of Cardiology and the American Heart Association Prac- Preamble tice Guidelines3,4). These recommendations provide a data-supported ap- proach to the diagnosis and treatment of patients with Introduction Wilson disease. They are based on the following: (1) for- Copper is an essential metal that is an important cofac- mal review and analysis of the recently-published world tor for many proteins. The average diet provides substan- literature on the topic including Medline search; (2) tial amounts of copper, typically 2-5 mg/day; the American College of Physicians Manual for Assessing recommended intake is 0.9 mg/day. Most dietary copper 1 Health Practices and Designing Practice Guidelines ; (3) ends up being excreted. Copper is absorbed by entero- guideline policies, including the AASLD Policy on the cytes mainly in the duodenum and proximal small intes- Development and Use of Practice Guidelines and the tine and transported in the portal circulation in American Gastroenterological Association Policy State- association with albumin and the amino acid histidine to 2 ment on Guidelines ; (4) the experience of the authors in the liver, where it is avidly removed from the circulation. the specified topic.
    [Show full text]
  • Practical Management of Iron Overload Disorder (IOD) in Black Rhinoceros (BR; Diceros Bicornis)
    animals Review Practical Management of Iron Overload Disorder (IOD) in Black Rhinoceros (BR; Diceros bicornis) Kathleen E. Sullivan, Natalie D. Mylniczenko , Steven E. Nelson Jr. , Brandy Coffin and Shana R. Lavin * Disney’s Animal Kingdom®, Animals, Science and Environment, Bay Lake, FL 32830, USA; [email protected] (K.E.S.); [email protected] (N.D.M.); [email protected] (S.E.N.J.); Brandy.Coffi[email protected] (B.C.) * Correspondence: [email protected]; Tel.: +1-407-938-1572 Received: 29 September 2020; Accepted: 26 October 2020; Published: 29 October 2020 Simple Summary: Black rhinoceros under human care are predisposed to Iron Overload Disorder that is unlike the hereditary condition seen in humans. We aim to address the black rhino caretaker community at multiple perspectives (keeper, curator, veterinarian, nutritionist, veterinary technician, and researcher) to describe approaches to Iron Overload Disorder in black rhinos and share learnings. This report includes sections on (1) background on how iron functions in comparative species and how Iron Overload Disorder appears to work in black rhinos, (2) practical recommendations for known diagnostics, (3) a brief review of current investigations on inflammatory and other potential biomarkers, (4) nutrition knowledge and advice as prevention, and (5) an overview of treatment options including information on chelation and details on performing large volume voluntary phlebotomy. The aim is to use evidence to support the successful management of this disorder to ensure optimal animal health, welfare, and longevity for a sustainable black rhinoceros population. Abstract: Critically endangered black rhinoceros (BR) under human care are predisposed to non-hemochromatosis Iron Overload Disorder (IOD).
    [Show full text]
  • Iron Deficiency Anemia: Evaluation and Management MATTHEW W
    Iron Deficiency Anemia: Evaluation and Management MATTHEW W. SHORT, LTC, MC, USA, and JASON E. DOMAGALSKI, MAJ, MC, USA Madigan Healthcare System, Tacoma, Washington Iron deficiency is the most common nutritional disorder worldwide and accounts for approxi- mately one-half of anemia cases. The diagnosis of iron deficiency anemia is confirmed by the findings of low iron stores and a hemoglobin level two standard deviations below normal. Women should be screened during pregnancy, and children screened at one year of age. Supple- mental iron may be given initially, followed by further workup if the patient is not responsive to therapy. Men and postmenopausal women should not be screened, but should be evaluated with gastrointestinal endoscopy if diagnosed with iron deficiency anemia. The underlying cause should be treated, and oral iron therapy can be initiated to replenish iron stores. Paren- teral therapy may be used in patients who cannot tolerate or absorb oral preparations. (Am Fam Physician. 2013;87(2):98-104. Copyright © 2013 American Academy of Family Physicians.) ▲ Patient information: ron deficiency anemia is diminished red causes of microcytosis include chronic A handout on iron defi- blood cell production due to low iron inflammatory states, lead poisoning, thalas- ciency anemia, written by 1 the authors of this article, stores in the body. It is the most com- semia, and sideroblastic anemia. is available at http://www. mon nutritional disorder worldwide The following diagnostic approach is rec- aafp.org/afp/2013/0115/ I and accounts for approximately one-half of ommended in patients with anemia and is p98-s1.html. Access to anemia cases.1,2 Iron deficiency anemia can outlined in Figure 1.2,6-11 A serum ferritin level the handout is free and unrestricted.
    [Show full text]
  • Ferriprox (Deferiprone) Tablets Contain 500 Mg Deferiprone (3-Hydroxy-1,2-Dimethylpyridin-4-One), a Synthetic, Orally Active, Iron-Chelating Agent
    HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use FERRIPROX safely and effectively. See full prescribing information for ------------------------------CONTRAINDICATIONS------------------------------- FERRIPROX. • Hypersensitivity to deferiprone or to any of the excipients in the FERRIPROX® (deferiprone) tablets, for oral use formulation. (4) Initial U.S. Approval: 2011 ------------------------WARNINGS AND PRECAUTIONS----------------------- WARNING: AGRANULOCYTOSIS/NEUTROPENIA • If infection occurs while on Ferriprox, interrupt therapy and monitor the See full prescribing information for complete boxed warning. ANC more frequently. (5.1) • Ferriprox can cause agranulocytosis that can lead to serious • Ferriprox can cause fetal harm. Women should be advised of the infections and death. Neutropenia may precede the development of potential hazard to the fetus and to avoid pregnancy while on this drug. agranulocytosis. (5.1) (5.3) • Measure the absolute neutrophil count (ANC) before starting Ferriprox and monitor the ANC weekly on therapy. (5.1) -----------------------------ADVERSE REACTIONS-------------------------------- • Interrupt Ferriprox if infection develops and monitor the ANC more frequently. (5.1) • The most common adverse reactions are (incidence ≥ 5%) chromaturia, • Advise patients taking Ferriprox to report immediately any nausea, vomiting and abdominal pain, alanine aminotransferase symptoms indicative of infection. (5.1) increased, arthralgia and neutropenia. (5.1, 6) -----------------------------INDICATIONS AND USAGE-------------------------- To report SUSPECTED ADVERSE REACTIONS, contact ApoPharma Inc. at: Telephone: 1-866-949-0995 FERRIPROX® (deferiprone) is an iron chelator indicated for the treatment of Email: [email protected] or FDA at 1-800-FDA-1088 or patients with transfusional iron overload due to thalassemia syndromes when www.fda.gov/medwatch current chelation therapy is inadequate. (1) Approval is based on a reduction in serum ferritin levels.
    [Show full text]
  • A Short Review of Iron Metabolism and Pathophysiology of Iron Disorders
    medicines Review A Short Review of Iron Metabolism and Pathophysiology of Iron Disorders Andronicos Yiannikourides 1 and Gladys O. Latunde-Dada 2,* 1 Faculty of Life Sciences and Medicine, Henriette Raphael House Guy’s Campus King’s College London, London SE1 1UL, UK 2 Department of Nutritional Sciences, School of Life Course Sciences, King’s College London, Franklin-Wilkins-Building, 150 Stamford Street, London SE1 9NH, UK * Correspondence: [email protected] Received: 30 June 2019; Accepted: 2 August 2019; Published: 5 August 2019 Abstract: Iron is a vital trace element for humans, as it plays a crucial role in oxygen transport, oxidative metabolism, cellular proliferation, and many catalytic reactions. To be beneficial, the amount of iron in the human body needs to be maintained within the ideal range. Iron metabolism is one of the most complex processes involving many organs and tissues, the interaction of which is critical for iron homeostasis. No active mechanism for iron excretion exists. Therefore, the amount of iron absorbed by the intestine is tightly controlled to balance the daily losses. The bone marrow is the prime iron consumer in the body, being the site for erythropoiesis, while the reticuloendothelial system is responsible for iron recycling through erythrocyte phagocytosis. The liver has important synthetic, storing, and regulatory functions in iron homeostasis. Among the numerous proteins involved in iron metabolism, hepcidin is a liver-derived peptide hormone, which is the master regulator of iron metabolism. This hormone acts in many target tissues and regulates systemic iron levels through a negative feedback mechanism. Hepcidin synthesis is controlled by several factors such as iron levels, anaemia, infection, inflammation, and erythropoietic activity.
    [Show full text]
  • Correlation Between Serum Bilirubin and Serum Ferritin Level in Thalassaemia Patients N Sultana1, S Sadiya2, MH Rahman1 1Dept
    ORIGINAL ARTICLE Correlation between serum bilirubin and serum ferritin Level in thalassaemia patients N Sultana1, S Sadiya2, MH Rahman1 1Dept. of Biochemistry, Dhaka Medical College, Dhaka 2Dept. of Biochemistry, Dhaka Shishu Hospital, Dhak ABSTRACT Thalassaemia is the most common hereditary disorder in the world including Bangladesh. Beta thalassaemia major and Hb-E thalassaemia both are common in our country. Iron overload causes most of the mortality and morbidity associate with thalassaemia. To assess the iron over load and liver function a cross sectional comparative study was carried out in the Department of Biochemistry, Dhaka Medical College, Dhaka in collaboration with Thalassaemia Center and Department of Pathology, Dhaka Shishu Hospital, Dhaka during the period of July 2006 to June 2007. The study was carried out with the patients who visited regularly in Dhaka Shishu Hospital Thalassaemia Centre (DSHTC) and had multiple transfusions (more than five) and age more than 2 years. To compare the state of liver function with normal healthy individuals' normal healthy persons were also included. Total 70 subjects were included in this study. The study subjects were distributed into two groups, the group - A (cases, n=40) and group - B (healthy controls, n=30). According to the major types of thalassaemia present in our country, group -A again divided into two, group - AI β-thalassaemia major (n=12) and group - AII of Hemoglobin E β-thalassaemia (n=28). The mean of serum Bilirubin in group - A and group - B were (2.04 ±0.70) mg/dl and (0.67±0.15) mg/dl respectively. Group - A had higher serum bilirubin than group -B in p value <0.001.The mean level of serum bilirubin in group - AI was (1.70±0.70)mg/dl and the mean of bilirubin in group AII was (2.18±0.66) mg/dl.
    [Show full text]